Curis raises $8.5 million in share and warrant offering
Curis signed a securities purchase agreement on October 16, 2026, for a financing expected to close October 19, 2026, with proceeds earmarked to carry the company through initial CLL trial data.
Curis, Inc. disclosed in an 8-K that on October 16, 2026 it entered into a Securities Purchase Agreement for the sale of 16,666,680 shares of common stock, or pre-funded warrants in place of shares, along with common warrants to purchase up to another 16,666,680 shares. The combined price was set at $0.51 per share and accompanying warrant, or $0.50 per pre-funded warrant and warrant.1
The common warrants carry a $0.60 exercise price, become exercisable six months after issuance and expire five and a half years from issuance, while the pre-funded warrants carry a one-cent exercise price and can be exercised immediately until fully used.1
Gross proceeds from the offering are expected to total approximately $8.5 million before placement fees and other expenses.1 The company said it plans to direct the net proceeds toward research and development activities as well as working capital and general corporate purposes.1 Curis added that the funding, combined with existing cash, should be enough to support operations through initial data from 5 to 10 patients in its chronic lymphocytic leukemia (CLL) program, expected in December 2026.1 The offering itself is slated to close on or about October 19, 2026, pending customary closing conditions.1
A.G.P./Alliance Global Partners served as lead placement agent, with Laidlaw & Company (UK) Ltd. acting as co-placement agent.1 Separately, Curis agreed to reduce the exercise price to $0.60 per share on existing Series A and Series C warrants from a January 2026 issuance covering 1,126,676 shares, as well as warrants from an August 2026 issuance covering 3,733,334 shares.1
Under a related registration rights agreement, Curis must file a resale registration statement within 30 days of the closing date.1 The placement agents are entitled to a 6.5% cash fee on gross proceeds, plus reimbursement of up to $85,000 in legal expenses and $10,000 in non-accountable expenses.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.